White coat hypertension: current state of the issue

Main Article Content

K. H. Uvarova


More than 30 years have passed since the first description of such a concept as white coat hypertension was presented in the scientific literature, but since then, scientists are paying more and more attention to this condition. White coat hypertension is defined when the blood pressure readings obtained in the doctor’s office meet the criteria for hypertension, but the latter is not confirmed by outpatient or home blood pressure monitoring. Initially, the term was only applied to patients who had not received antihypertensive treatment, but recently this definition has been extended to people who regularly take drugs for lowering blood pressure, and this condition was called uncontrolled white coat hypertension. Some of the world’s most influential organizations in the field of cardiology have not reached a consensus on the definition of white coat hypertension on the background of common criteria, which has affected the differences in blood pressure thresholds according to outpatient monitoring. Quite a few studies in recent years have examined the clinical and prognostic significance of white coat hypertension in terms of its probable effects such as metabolic disorders, subclinical and extracardiac target organ damage, cardiovascular morbidity and mortality, and all-cause mortality. At present, there is no doubt that white coat hypertension is not an innocent condition; however, hypotheses about the prognostic role of this condition and the management of patients with white coat hypertension are still controversial. The question of treating white coat hypertension as a condition remains unsolved and requires further investigation. Today, it is considered most appropriate not to prescribe antihypertensive treatment to persons with office blood pressure at normal or below target levels, but to intensify lifestyle modifications and focus on reduction of cardiovascular risk.

Article Details


white coat hypertension, ambulatory blood pressure monitoring


Allgulander C. Anxiety as a risk factor in cardiovascular disease // Curr. Opinion in Psychiatry.– 2008.– Vol. 29 (1).– P. 13–17. doi: https://doi.org/10.1097/YCO.0000000000000217.

Banegas J.R., Ruilope L.M., de la Sierra A. et al. Relationship between clinic and ambulatory blood pressure measurements and mortality // New Engl. J. Med.– 2018.– Vol. 378 (16).– P. 1509–1520. doi: https://doi.org/10.1056/NEJMoa1712231.

Bloomfield D.A., Park A. Decoding white coat hypertension // World J. Clin. Cases.– 2017.– Vol. 5 (3).– P. 82. doi: https://doi.org/10.12998/wjcc.v5.i3.82.

Briasoulis A., Androulakis E., Palla M. et al. White-coat hypertension and cardiovascular events: a meta-analysis // J. Hypertension.– 2016.– Vol. 34 (4).– P. 593–599. doi: https://doi.org/10.1097/HJH.0000000000000832.

Bromfield S.G., Ngameni C.A., Colantonio L.D. et al. Blood pressure, antihypertensive polypharmacy, frailty, and risk for serious fall injuries among older treated adults with hypertension // Hypertension.– 2017.– Vol. 70 (2).– P. 259–266. doi: https://doi.org/10.1161/HYPERTENSIONAHA.116.09390.

Bulpitt C.J., Beckett N., Peters R. et al. Does white coat hypertension require treatment over age 80? Results of the hypertension in the very elderly trial ambulatory blood pressure side project // Hypertension.– 2013.– Vol. 61 (1).– P. 89–94. doi: https://doi.org/10.1161/HYPERTENSIONAHA.112.191791.

Cohen J.B., Lotito M.J., Trivedi U.K. et al. Cardiovascular events and mortality in white coat hypertension: a systematic review and meta-analysis // Ann. Intern. Med.– 2019.– Vol. 170 (12).– P. 853–862. doi: https://doi.org/10.7326/M19-0223.

Cuspidi C., Rescaldani M., Tadic M. et al. White-coat hypertension, as defined by ambulatory blood pressure monito­­ring, and subclinical cardiac organ damage: a meta-analysis // J. Hypertension.– 2015.– Vol. 33 (1).– P. 24–32. doi: https://doi.org/10.1097/HJH.0000000000000416.

Cuspidi C., Sala C., Tadic M. et al. Is white-coat hypertension a risk factor for carotid atherosclerosis? A review and meta-analysis // Blood pressure monitoring.– 2015.– Vol. 20 (2).– P. 57–63. doi: https://doi.org/10.1097/MBP.0000000000000094.

De la Sierra A., Vinyoles E., Banegas J.R. et al. Prevalence and clinical characteristics of white-coat hypertension based on different definition criteria in untreated and treated patients // J. Hypertension.– 2017.– Vol. 35 (12).– P. 2388–2394. doi: https://doi.org/10.1097/HJH.0000000000001493.

De la Sierra A., Vinyoles E., Banegas J.R. et al. Short-term and long-term reproducibility of hypertension phenotypes obtained by office and ambulatory blood pressure measurements // J. Clin. Hypertension.– 2016.– Vol. 18 (9).– P. 927–933. doi: https://doi.org/10.1111/jch.12792.

Franklin S.S., Thijs L., Asayama K. et al. The cardiovascular risk of white-coat hypertension // J. Amer. Coll. Cardiology.– 2016.– Vol. (19).– P. 2033–2043.

Fukuhara M., Arima H., Ninomiya T. et al. White-coat and masked hypertension are associated with carotid atherosclerosis in a general population: the Hisayama study // Stroke.– 2013.– Vol. 44 (6).– P. 1512–1517. doi: https://doi.org/10.1161/STROKEAHA.111.000704.

Gorostidi M., Vinyoles E., Banegas J. R. et al. Prevalence of white-coat and masked hypertension in national and international registries // Hypertension Research.– 2015.– Vol. 38 (1).– P. 1–7. doi: https://doi.org/10.1038/hr.2014.149

Huang Y., Huang W., Mai W. et al. White-coat hypertension is a risk factor for cardiovascular diseases and total mortality // J. Hypertension.– 2017.– Vol. 35 (4).– P. 677. doi: https://doi.org/10.1097/HJH.0000000000001226.

Mancia G., Bombelli M., Brambilla G. et al. Long-term prognostic value of white coat hypertension: an insight from diagnostic use of both ambulatory and home blood pressure measurements // Hypertension.– 2013.– Vol. 62 (1).– P. 168–174. doi: https://doi.org/10.1161/HYPERTENSIONAHA.111.00690

Mancia G., Facchetti R., Cuspidi C. et al. Limited reprodu­cibility of MUCH and WUCH: evidence from the ELSA study // Eur. Heart J.– 2020.– Vol. 41 (16).– P. 1565-1571. doi: https://doi.org/10.1093/eurheartj/ehz651.

Muntner P., Einhorn P. T., Cushman W. C. et al. Blood pressure assessment in adults in clinical practice and clinic-based research: JACC scientific expert panel // J. Amer. Coll. Cardiology.– 2019.– Vol. 73 (3).– P. 317–335. doi: https://doi.org/10.1016/j.jacc.2018.10.069

Myers M.G., Stergiou G.S. White coat phenomenon: removing the stigma of hypertension // Hypertension.– 2016.– Vol. 67.– P. 1111–1113. doi: https://doi.org/10.1161/HYPERTENSIONAHA.116.07322.

Jones N.R., McCormack T., Constanti M. et al. Diagnosis and management of hypertension in adults: NICE guideline update 2019 // Brit. J. General Practice.– 2020.– Vol. 70 (691).– P. 90–91. doi: https://doi.org/10.3399/bjgp20X708053.

Noubiap J.J., Nansseu J.R., Nkeck J.R. et al. J. Prevalence of white coat and masked hypertension in Africa: A systematic review and meta-analysis // J. Clin. Hypertension.– 2018.– Vol. 20 (8).– P. 1165–1172. doi: https://doi.org/10.1111/jch.13321.

Nuredini G., Saunders A., Rajkumar C., Okorie M. Current status of white coat hypertension: where are we? // Therapeutic Advances in Cardiovascular Disease.– 2020.– Vol. 14.– P. 1753944720931637. doi: https://doi.org/10.1177%2F1753944720931637.

O’Brien E., Parati G., Stergiou G. et al. European Society of Hypertension position paper on ambulatory blood pressure monitoring // J. Hypertension.– 2013.– Vol. 31 (9).– P. 1731–1768. doi: https://doi.org/10.1097/HJH.0b013e328363e964.

O’Brien E., Asmar R., Beilin L. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement // J. Hypertension.– 2003.– Vol. 21 (5).– P. 821–848. doi: https://doi.org/10.1097/00004872-200305000-00001.

Pierdomenico S.D., Cuccurullo F. Prognostic value of white-coat and masked hypertension diagnosed by ambulatory monitoring in initially untreated subjects: an updated meta analysis // Amer. J. Hypertension.– 2011.– Vol. 24 (1).– P. 52–58. doi: https://doi.org/10.1038/ajh.2010.203.

Roush G.C., Fagard R.H., Salles G.F. Prognostic impact from clinic, daytime, and night-time systolic blood pressure in nine cohorts of 13 844 patients with hypertension // J. Hypertension.– 2014.– Vol. 32 (12).– P. 2332–2340. doi: https://doi.org/10.1097/HJH.0000000000000355.

Schiffrin E.L., Calhoun D.A., Flack J.M. SPRINT Proves that Lower Is Better for Nondiabetic High-Risk Patients, but at a Price // Amer. J. Hypertension.– 2016.– Vol. 29 (1).– P. 2–4. doi: https://doi.org/10.1093/ajh/hpv190.

Shimbo D., Barrett Bowling C., Levitan E.B. et al. 2016. Short-term risk of serious fall injuries in older adults initiating and intensifying treatment with antihypertensive medication // Circulation: Cardiovascular Quality and Outcomes.– 2016.– Vol. 9 (3).– P. 222-229. doi: https://doi.org/10.1161/CIRCOUTCOMES.115.002524.

Sivén S.S., Niiranen T.J., Kantola I.M. White-coat and masked hypertension as risk factors for progression to sustained hypertension: the Finn-Home study // J. Hypertension.– 2016.– Vol. 34 (1).– P. 54–60. doi: https://doi.org/10.1097/HJH.0000000000000750.

SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control // New Engl. J. Med.– 2015.– Vol. 373 (22).– P. 2103–2116. doi: https://doi.org/10.1056/NEJMoa1511939.

Tadic M., Cuspidi C., Ivanovic B. The impact of white-coat hypertension on cardiac mechanics // J. Clin. Hypertension.– 2016.– Vol. 18 (7).– P. 617–622. doi: https://doi.org/10.1111/jch.12826.

Terracciano A., Scuteri A., Strait J. et al. Are personality traits associated with white coat and masked hypertension? // J. Hypertension.– 2014.– Vol. 32 (10).– P. 1987. doi: https://doi.org/10.1097%2FHJH.0000000000000289.

Tientcheu D., Ayers C., Das S.R. et al. Target organ complications and cardiovascular events associated with masked hypertension and white-coat hypertension: analysis from the Dallas Heart Study // J. Amer. Coll. Cardiology.– 2015.– Vol. 66 (20).– P. 2159–2169. doi: https://doi.org/10.1016/j.jacc.2015.09.007.

Tocci G., Presta V., Figliuzzi I. et al. Prevalence and clinical outcomes of white-coat and masked hypertension: analysis of a large ambulatory blood pressure database // J. Clin. Hypertension.– 2018.– Vol. 20 (2).– P. 297–305. doi: https://doi.org/10.1111/jch.13181.

Ugajin T., Hozawa A., Ohkubo T. et al. White-coat hypertension as a risk factor for the development of home hypertension: the Ohasama study // Arch. Intern. Medicine.– 2005.– Vol. 165 (13).– P. 1541–1546. doi: https://doi.org/10.1001/archinte.165.13.1541.

Whelton P.K., Robert M.C., Wilbert S.A. et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/ NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines // J. Amer. Coll. Cardiology.– 2018.– Vol. 71 (19).– P. 127–248. doi: https://doi.org/10.1161/HYP.0000000000000065.

Williams B., Mancia G., Spiering W. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH) // Eur. Heart J.– 2018.– Vol. 39 (33).– P. 3021–3104. doi: https://doi.org/10.1093/eurheartj/ehy339.

Xiang H., Xue Y., Wang J. et al. Cardiovascular alterations and management of patients with white coat hypertension: a meta-analysis // Front. Pharmacology.– 2020.– Vol. 11.– P. 1498. doi: https://doi.org/10.3389/fphar.2020.570101.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>